Understanding Multiple Myeloma and Its Treatment
What is Multiple Myeloma?
Multiple myeloma (MM) is a serious cancer that affects the bone marrow, specifically targeting plasma cells. These cells play a crucial role in the immune system by producing antibodies that help defend against infections. When plasma cells become cancerous, they disrupt the bone marrow’s ability to generate red blood cells, leading to anemia, fatigue, weight loss, and other significant health issues.
Statistics on Multiple Myeloma in Canada
In 2017, Statistics Canada reported that 2,900 Canadians were diagnosed with multiple myeloma, resulting in 1,450 deaths attributed to the disease. With a five-year survival rate of just 42%, multiple myeloma remains one of the most lethal cancers affecting Canadians.
Stem Cell Transplant: The Gold Standard Treatment
Overview of Stem Cell Transplantation
For over 35 years, autologous stem cell transplant has been considered the gold standard in treating multiple myeloma. This procedure involves collecting healthy stem cells from a donor and transplanting them into the patient to restore healthy bone marrow.
Emerging Concerns and New Research
As new anti-cancer therapies have emerged, the effectiveness and safety of stem cell transplants have come under scrutiny. A recent study published in the Mayo Clinic Proceedings examined the safety of stem cell transplants in multiple myeloma patients.
Study Details and Findings
The researchers monitored 1,078 multiple myeloma patients who underwent stem cell transplants at the Mayo Clinic between January 1, 2008, and May 1, 2017. They tracked the patients for 100 days to assess survival rates and the duration of inpatient stays post-transplant.
Results of the Study
The study revealed a 100-day survival rate of 99.7% among patients who received stem cell transplants, with a median inpatient stay of zero days. This indicates that the procedure is a safe treatment option for multiple myeloma, with a low incidence of severe complications. Among the 1,078 patients monitored, only three died within 100 days post-transplant, primarily due to existing health conditions. Notably, no patients over 65 years old died during the study, although some patients over 75 experienced an average inpatient stay of four days, suggesting a slightly higher risk for older individuals, yet the procedure remains relatively safe.
Conclusion
The study conducted at the Mayo Clinic reaffirms that stem cell transplantation remains the gold standard for treating multiple myeloma, demonstrating minimal risks of complications. As new treatment options continue to develop, the role of stem cell transplants in patient care will be essential to evaluate.
References
(1) Hogan, W, et al. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clinic. 2018.
(2) Canadian Cancer Society. Canadian Cancer Statistics 2017. Cancer Soc. 2017, 1–132 (2017).